Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma

NCT01387932 is registered in ClinicalTrials.gov with Merit Medical Systems, Inc. as lead sponsor.

NCT NCT01387932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01387932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Lead sponsor
Merit Medical Systems, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2011
Completion date
February 28, 2021
Enrollment
235 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma